Effect of newer oral antiviral agents on future therapy of chronic hepatitis B

被引:6
|
作者
Perrillo, Robert P. [1 ]
Marcellin, Patrick [2 ]
机构
[1] Baylor Univ, Med Ctr, Dallas, TX USA
[2] Hop Beaujon, Dept Hepatol, Clichy, France
关键词
POSITIVE CHRONIC HEPATITIS; TENOFOVIR DISOPROXIL FUMARATE; NUCLEOSIDE-NAIVE PATIENTS; VIRUS POLYMERASE MUTATIONS; LONG-TERM THERAPY; ADV SWITCH DATA; ADEFOVIR DIPIVOXIL; E-ANTIGEN; LAMIVUDINE THERAPY; DNA REDUCTION;
D O I
10.3851/IMP1482
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Long-term therapy with oral nucleoside/nucleotide analogues (NAs) is a favoured approach to the treatment of patients with chronic hepatitis B (CHB); however, all oral agents currently approved for the treatment of such patients are associated with some risk for drug resistance. This can lead to a rebound in HBV levels and, eventually, progressive liver disease. Combination therapy is one strategy that has the potential for enhanced antiviral effects and diminished or delayed resistance. The disadvantages of combination therapy include increased cost, the potential for drug interactions and increased toxicity. Additional therapeutic efficacy from combination therapy has not been demonstrated in clinical trials of HBV, and this approach might be less relevant now that potent NAs with excellent drug resistance profiles are available. However, it might be possible to identify subsets of patients (for example, those with extremely high viraemia or low baseline alanine aminotransferase levels) who derive added benefit from combination therapy. This review examines efficacy and resistance data for new low resistance oral NAs and clinical experience to date with de novo combination therapy in patients with CHB. The application of combination therapy in select populations of patients with CHB is also discussed.
引用
收藏
页码:13 / 22
页数:10
相关论文
共 50 条
  • [21] Antiviral Therapy for Chronic Hepatitis B in Pregnancy
    Pan, Calvin Q.
    Lee, Hannah M.
    SEMINARS IN LIVER DISEASE, 2013, 33 (02) : 138 - 146
  • [22] ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS-B
    HESS, G
    MEYER, KH
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1985, 110 (31-3) : 1230 - 1230
  • [23] Antiviral therapy for chronic hepatitis B in China
    Zheng, Xin
    Wang, Junzhong
    Yang, Dongliang
    MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 2015, 204 (01) : 115 - 120
  • [24] The Evaluation of Antiviral Therapy in Chronic Hepatitis B
    Gunal, Ozgur
    Hizel, Kenan
    Guzel, Ozlem
    Dizbay, Murat
    Ulutan, Fatma
    Arman, Dilek
    VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, 2006, 11 (02): : 65 - 69
  • [25] ANTIVIRAL THERAPY OF CHRONIC HEPATITIS-B
    KOKOREVA, LN
    ZMYZGOVA, AV
    TERAPEVTICHESKII ARKHIV, 1995, 67 (02) : 65 - 68
  • [26] A COMPREHENSIVE ANALYSIS FOR RENAL OUTCOMES IN PATIENTS RECEIVING ORAL ANTIVIRAL AGENTS FOR CHRONIC HEPATITIS B
    Son, Seung Yeon
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
  • [28] Oral antiviral therapy for HBeAg negative chronic hepatitis B: better stop or continue?
    Lampertico, Pietro
    GUT, 2015, 64 (04) : 526 - U218
  • [29] ANTIVIRAL AGENTS IN CHRONIC HEPATITIS
    HOUSSET, C
    BERTHELOT, P
    BRECHOT, C
    GAZETTE MEDICALE, 1989, 96 (43): : 21 - &
  • [30] Discontinuation of antiviral therapy in chronic hepatitis B patients
    Renato Medas
    Rodrigo Liberal
    Guilherme Macedo
    World Journal of Clinical Cases, 2021, (24) : 6979 - 6986